Camilla Mattiuzzi

Dr. Camilla Mattiuzzi

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2020 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
Giuseppe LippiGiuseppe Lippi
Giuseppe Lippi
Camilla MattiuzziCamilla Mattiuzzi
Camilla Mattiuzzi
FSFabian Sanchis-Gomar
Fabian Sanchis-Gomar
Brandon Michael HenryBrandon Michael Henry
Brandon Michael Henry

11 May 2020
Verified
Journal Article
Open access
Giuseppe LippiGiuseppe Lippi
Giuseppe Lippi
Camilla MattiuzziCamilla Mattiuzzi
Camilla Mattiuzzi
CBChiara Bovo
Chiara Bovo
Mario PlebaniMario Plebani
Mario Plebani
Laboratory medicine provides an almost irreplaceable contribution to the diagnostic reasoning and managed care of most human pathologies. The novel coronavirus disease 2019 (COVID-19) is not an exception to this paradigm. Although the relatively recent emergence does not allow to draw definitive conclusions on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnostics, some standpoints can be conveyed. First and foremost, it seems now clear that we will be living together with this virus for quite a long time, so that our vigilance and responsiveness against the emergence of new local outbreaks shall be maintained at the highest possible levels. The etiological diagnosis of COVID-19 is, and will remain for the foreseeable future, deeply based on direct identification of viral RNA by means of molecular biology techniques in biological materials, especially upper and lower respiratory tract specimens. Whether other materials, such as blood, urine, stools, saliva and throat washing, will become valid alternatives has not been unequivocally defined so far. As concerns serological testing, promising information can be garnered from preliminary investigations, showing that the vast majority of COVID-19 patients seem to develop a sustained immune response against the virus, characterized especially by emergence of anti-SARS-CoV-2 IgG and IgA, 1 to 2 weeks after the onset of fever and/or respiratory symptoms. Whether these antibodies will have persistent neutralizing activity against the virus is still to be elucidated on individual and general basis. The availability of rapid tests for detecting either viral antigens or anti-SARS-CoV-2 antibodies are a potentially viable opportunity for purposes of epidemiologic surveillance, though more information is needed on accuracy and reliability of these portable immunoassays.

1 July 2017 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
Giuseppe LippiGiuseppe Lippi
Giuseppe Lippi
Camilla MattiuzziCamilla Mattiuzzi
Camilla Mattiuzzi
Martina MontagnanaMartina Montagnana
Martina Montagnana
The pathogenesis of breast cancer, the most frequent female malignancy, entails both genetic and acquired risk factors. Among the various oncogenetic mutations, those involving the BReast Cancer 1 (BRCA1) and BReast Cancer 2 (BRCA2) genes are associated with an extremely high risk of developing breast cancer, with a penetration approximating 70% in women with a positive family history for this malignancy. This important evidence elicits some pragmatic considerations, such as the clinical effectiveness of screening for the most penetrant BRCA mutations in women with or without a positive familial history, but also raises important issues related to the most appropriate clinical management of these patients. Despite it seems now almost certain that BRCA testing should be offered to women with a positive familial history for breast cancer, the balance between advantages and limitations of a population screening remains largely debated. Whatever conclusion can be reach at this point in time must be accurately weighed against at least four different perspectives, which include the low prevalence of these mutations in the general population, the relatively lower risk of developing breast cancer in women without a familial history for this malignancy, the direct and indirect cost of genetic testing and, last but not least, the many potential psychological and clinical consequences in patients receiving a positive test result. Many of these still unresolved issues will be tentatively discussed in this article.

7 September 2020
Verified
Journal Article
Open access
Camilla MattiuzziCamilla Mattiuzzi
Camilla Mattiuzzi
Brandon Michael HenryBrandon Michael Henry
Brandon Michael Henry
FSFabian Sanchis-Gomar
Fabian Sanchis-Gomar
Giuseppe LippiGiuseppe Lippi
Giuseppe Lippi
Isolation of subjects with active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a pivotal preventive measure in the ongoing coronavirus disease 2019 (COVID-19) pandemic. A growing number of studies reported cases of recurrent SARS-CoV-2 RNA positivity following disease recovery, which were identified with a critical literature search and then meta-analyzed in this article. A digital search was performed in Medline and Web of Science, using the keywords “coronavirus disease 2019” OR “COVID-19” OR “severe acute respiratory disease 2” OR “SARS-CoV-2” AND “recurrence” OR “repositivization” OR “retesting”, without date or language restrictions. Recovery was defined as resolution of symptoms, with at least two consecutive negative molecular tests. A total number of 17 studies, with 5,182 COVID-19 patients, were included. SARS-CoV-2 recurrent RNA positivity in recovered COVID-19 patients ranged between 7-23% across the studies, with follow-up testing between 1-60 days. The estimated cumulative rate of SARS-CoV-2 recurrent RNA positivity was 12% (95% confidence interval, 12-13%; I2, 74%). Repeated molecular testing on respiratory tracts specimens at 1 and 2 months after recovery from COVID-19 is strongly advisable for early identification, isolation and clinical management of subjects with SARS-CoV-2 recurrent RNA positivity. (www.actabiomedica.it)

7 September 2020
Verified
Journal Article
Open access
Giuseppe LippiGiuseppe Lippi
Giuseppe Lippi
Camilla MattiuzziCamilla Mattiuzzi
Camilla Mattiuzzi
GCGianfranco Cervellin
Gianfranco Cervellin
Digital epidemiology is increasingly used for supporting traditional epidemiology. This study was hence aimed to explore whether the Google search volume may have been useful to predict the trajectory of coronavirus disease 2019 (COVID-19) outbreak in Italy. We accessed Google Trends for collecting data on weekly Google searches for the keywords "tosse" (i.e., cough), "febbre" (i.e., fever) and "dispnea" (dyspnea) in Italy, between February and May 2020. The number of new weekly cases of COVID-19 in Italy was also obtained from the website of the National Institute of Health. The peaks of Google searches for the three terms predicted by 3 weeks that of newly diagnosed COVID-19 cases. The peaks of weekly Google searches for "febbre" (fever), "tosse"( cough) and "dispnea" (dyspnea) were 1.7-, 2.2- and 7.7-fold higher compared to the week before the diagnosis of the first national case. No significant correlation was found between the number of newly diagnosed COVID-19 cases and Google search volumes of "tosse" (cough) and "febbre" (fever), whilst "dyspnea" (dyspnea) was significantly correlated (r= 0.50; p=0.034). The correlation between newly diagnosed COVID-19 cases and "tosse" (cough; r=0.65; p=0.008) or "febbre" (fever; 0.69; p=0.004) become statistically significant with a 3-week delay. All symptoms were also significantly inter-correlated. Conclusions; Continuously monitoring the volume of Google searches and mapping their origin can be a potentially valuable instrument to help predicting and identifying local recrudescence of COVID-19.